Macular Degeneration Clinical Trials in Erie, Pennsylvania
16 recruitingErie, Pennsylvania
Showing 1–16 of 16 trials
Recruiting
Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled51 locationsNCT04853251
Recruiting
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.500 enrolled65 locationsNCT06779773
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled28 locationsNCT07441642
Recruiting
Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
AbbVie561 enrolled128 locationsNCT07007065
Recruiting
Phase 3
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Age related macular degeneration (AMD)Geographic Atrophy (GA)
Regeneron Pharmaceuticals975 enrolled216 locationsNCT06541704
Recruiting
Phase 1Phase 2
Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration
Neovascular (Wet) Age-related Macular Degeneration
Eyconis INC.30 enrolled5 locationsNCT07587515
Recruiting
Phase 2Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled9 locationsNCT07496567
Recruiting
Phase 2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Geographic Atrophy secondary to Age Related Macular Degeneration
ADARx Pharmaceuticals, Inc.240 enrolled24 locationsNCT06990269
Recruiting
Phase 3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
Age-Related Macular Degeneration
University of Wisconsin, Madison1,000 enrolled14 locationsNCT06924021
Recruiting
Phase 1Phase 2
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-Related Macular Degeneration (nAMD)
Alcon Research140 enrolled42 locationsNCT05769153
Recruiting
Not Applicable
Ocular Proteomics Testing In Chronic Atrophy
Age-Related (Dry) Macular Degeneration
ClinOmicsAI50 enrolled1 locationNCT07298291
Recruiting
Phase 2
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Age related macular degeneration (AMD)Geographic Atrophy (GA)
ONL Therapeutics324 enrolled28 locationsNCT06659445
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577
Recruiting
Phase 1
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Age-related Wet Macular Degeneration
Caregen Co. Ltd.45 enrolled7 locationsNCT06132035